

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2023- 24/017

August 10, 2023

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 532637

Listing Department
**National Stock Exchange of
India Limited**
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Outcome of Board Meeting held on Thursday, August 10, 2023

Dear Sir / Madam,

Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations) we wish to inform that the Board of Directors of the Company at its meeting held today i.e., August 10, 2023 *inter-alia* transacted the following business:

1. Considered & approved the Un-Audited Financial Results for the quarter ended June 30, 2023 along with the Limited Review Report on the results pursuant to Regulation 33 of the Listing Regulations; (Annexure A)

The meeting of Board of Directors of the Company commenced at 04:00 p.m. and concluded at 5:30 p.m.

We request you to take the same on your records & Oblige.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

The Board of Directors,
Mangalam Drugs and Organics Limited,
Rupam Building, 3rd Floor,
239, P. D'Mello Road, Mumbai 400 001.

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




4. Conclusion:

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: August 10, 2023

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W



C.A. Vidyadhar Somani
Proprietor

Membership No.102664

UDIN No. 23102664BQUQJS7795



MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.




Unaudited Financial Results for the Quarter Ended 30th June 2023 approved and taken on record by the Board at their meeting dated 10 th August, 2023

| Sr.No | Particulars | Quarter Ended | | | (Rs. In Lacs) |
|-------|--|-------------------|-----------------|------------------|------------------|
| | | 30.06.23 | 31.03.2023 | 30.06.2022 | Year Ended |
| | | Unaudited | Audited | Unaudited | Audited |
| 1 | Income from Operations | | | | |
| | (a) Net Sales and Services from Operations | 8,700.34 | 9,027.20 | 10,946.64 | 37,019.54 |
| | (b) Other Operating Income | 46.46 | 83.53 | 2.85 | 205.75 |
| | Total Income from Operations (net) (a+b) | 8,746.80 | 9,110.73 | 10,949.49 | 37,225.29 |
| 2 | Expenses | | | | |
| | (a) Cost of Materials Consumed | 5,966.20 | 5,503.00 | 8,217.21 | 27,744.95 |
| | (b) Purchase of Stock in trade | 0.24 | 92.79 | 101.03 | 1535.52 |
| | (c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade | 620.72 | 1,496.95 | (924.69) | (4,216.11) |
| | (d) Employee Benefits Expenses | 888.53 | 628.52 | 935.60 | 3,461.23 |
| | (e) Depreciation and amortization expenses | 341.86 | 274.96 | 260.01 | 1,098.89 |
| | (f) Other Expenses | 1,618.56 | 1,365.22 | 1,582.72 | 6,147.86 |
| | Total Expenses (a to f) | 9,436.11 | 9,361.42 | 10,171.88 | 35,772.34 |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | (689.31) | (250.69) | 777.61 | 1,452.95 |
| 4 | Other Income | 1.96 | 29.22 | 0.66 | 43.56 |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) | (687.35) | (221.47) | 778.27 | 1,496.51 |
| 6 | Finance costs (net) | 341.19 | 343.40 | 354.48 | 1,275.13 |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) | (1,028.54) | (564.87) | 423.79 | 221.38 |
| 8 | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | Profit/(Loss) from ordinary activities before tax (7-8) | (1,028.54) | (564.87) | 423.79 | 221.38 |
| 10 | Tax Expenses | | | | |
| | (a) Current Tax | - | (228.32) | 133.01 | (2.62) |
| | Mat Credit Entitlement | | | | |
| | (b) Deferred Tax | (75.00) | 102.00 | (9.60) | 97.00 |
| | Total Tax Expenses (a+b) | (75.00) | (126.32) | 123.41 | 94.38 |
| 11 | Net Profit(+)/Loss(-) from ordinary activities after tax (9-10) | (953.54) | (438.55) | 300.38 | 127.00 |
| 12 | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 | Net Profit(+)/Loss (-) for the period(11-12) | (953.54) | (438.55) | 300.38 | 127.00 |
| 14 | Share of Profit / (Loss) of associates | | | | |
| 15 | Minority Interest | | | | |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15) | (953.54) | (438.55) | 300.38 | 127.00 |
| 17 | Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes) | 3.12 | 21.32 | 2.95 | 12.48 |
| 18 | Total Comprehensive Income (16+17) | (950.42) | (417.23) | 303.33 | 139.48 |
| 18 | Paid-up Equity Share Capital (Face value of Rs 10/- per share) | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 |
| 19 | Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year | | | | 13,612.80 |
| 20 | Earnings Per Share (EPS) (of Rs 10/-each not annualised): | | | | |
| | (a) Basic | (6.02) | (2.77) | 1.90 | 0.80 |
| | (b) Diluted | (6.02) | (2.77) | 1.90 | 0.80 |




| Notes | |
|-------|---|
| 1 | The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendments rules thereafter. |
| 2 | The above unaudited financial results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on August 10, 2023. The Statutory Auditors have completed limited review report |
| 3 | As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments". |
| 4 | The figures of the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of full financial year upto March 31, 2023 and the unaudited published year-to-date figures upto December 31, 2022 being the date of the end of the third quarter of financial year respectively which were subjected to limited review. |
| 5 | Figures for the previous periods have been regrouped / re-classified to conform with the figures of the current period. |

On behalf of Board of Directors
For Mangalam Drugs and Organics Limited



Shri Govardhan M. Dhoot
Chairman and Managing Director
DIN:01240086



Place: Mumbai
Date: August 10, 2023

